Hannah Valantine Sells 2,196 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,196 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total value of $150,579.72. Following the completion of the sale, the director owned 9,259 shares of the company’s stock, valued at approximately $634,889.63. This trade represents a 19.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Monday, June 22nd, Hannah Valantine sold 2,808 shares of BridgeBio Pharma stock. The stock was sold at an average price of $68.00, for a total value of $190,944.00.

BridgeBio Pharma Trading Up 0.5%

Shares of BridgeBio Pharma stock opened at $69.69 on Friday. The company’s 50-day moving average price is $69.03 and its two-hundred day moving average price is $71.84. BridgeBio Pharma, Inc. has a 52 week low of $41.80 and a 52 week high of $84.94. The stock has a market cap of $13.65 billion, a PE ratio of -18.63 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The business had revenue of $194.51 million for the quarter, compared to the consensus estimate of $178.07 million. During the same period last year, the firm earned ($0.88) earnings per share. The company’s revenue was up 66.8% compared to the same quarter last year. On average, equities analysts predict that BridgeBio Pharma, Inc. will post -2.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on BBIO shares. HC Wainwright restated a “buy” rating and set a $110.00 target price on shares of BridgeBio Pharma in a report on Thursday, May 28th. Raymond James Financial cut BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 26th. Royal Bank Of Canada began coverage on BridgeBio Pharma in a research report on Thursday, April 9th. They set an “outperform” rating and a $100.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. Finally, JPMorgan Chase & Co. lifted their target price on BridgeBio Pharma from $89.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, March 10th. Twenty-one equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $92.90.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. TD Asset Management Inc acquired a new stake in shares of BridgeBio Pharma during the third quarter worth approximately $4,620,000. HighVista Strategies LLC increased its stake in BridgeBio Pharma by 21.4% in the 3rd quarter. HighVista Strategies LLC now owns 81,959 shares of the company’s stock valued at $4,257,000 after buying an additional 14,460 shares during the period. Central Pacific Bank Trust Division acquired a new position in BridgeBio Pharma in the 4th quarter valued at approximately $789,000. Allspring Global Investments Holdings LLC lifted its position in BridgeBio Pharma by 14,211.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 994,220 shares of the company’s stock worth $77,783,000 after buying an additional 987,273 shares in the last quarter. Finally, Okabena Investment Services Inc. purchased a new stake in BridgeBio Pharma in the 3rd quarter worth approximately $816,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.